Efgartigimod injections for adults with Graves' disease not controlled by thyroid medicines
Tests efgartigimod against placebo in adults with Graves' disease on antithyroid drugs.
Key facts
- Who runs it
- argenx
- Where
- Albany, Ann Arbor, Asheville, Carlsbad, Dallas, Dearborn, El Paso, Farmington Hills, Fleming Island, Fort Lauderdale, Houston, Irving, Jacksonville, Kansas City, Kissimmee, Lenexa, McAllen, McKinney, Mesquite, Miami, New York, Orange, Pasadena, Raleigh, San Jose, Shavano Park, and Wichita, United StatesSee the 29 sitesAlso in 2 other countries, 6 sites
- Trial code
- Registry title
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 230 people, planned
- Started
- 10 Jun 2026
- Expected to end
- May 2030
- Type of study
- Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Efgartigimod PH20 SC
- Placebo PH20 SC
- Record updated
- 3 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Graves' disease whose overactive thyroid is not well controlled by antithyroid drugs.
- Age
- 18 years or older, and at least the local legal age of consent for clinical studies.
- Sex
- All sexes can join.
- Disease stage
- Active hyperthyroidism (overactive thyroid) caused by Graves' disease, with TSH (thyroid-stimulating hormone) <0.1 mIU/L at screening.
- Earlier treatment
- People must have taken MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening. People who had RAI (radioactive iodine) therapy or total removal of the thyroid cannot join.
- Biomarker or test result
- TRAb (anti-thyrotropin receptor antibody) levels at or above the upper limit of normal at screening.
Main reasons for not taking part
- Overactive thyroid not caused by Graves' disease, such as toxic adenoma or toxic multinodular goiter.
- Past RAI (radioactive iodine) therapy or total thyroid removal.
- T3- or T4-containing medicine or supplement, such as levothyroxine, taken <6 weeks before screening.
- Heart rhythm problems linked to Graves' disease, such as atrial fibrillation, not controlled enough with medicines.
- Graves' eye disease that needs whole-body treatment, eye-socket injections, surgery or radiation, or such treatment planned during the study.
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF
- Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels >=ULN (upper limit of normal) at screening
- Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) <0.1 mIU/L at screening
- Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening
Who cannot take part
- History of RAI (radioactive iodine) therapy or received a total thyroidectomy
- T3- or T4-containing medication or supplement (eg, levothyroxine, liothyronine, desiccated thyroid preparations, or thyroid-support supplements) received <6 weeks before screening
- History of hyperthyroidism not caused by GD (eg, toxic adenoma or toxic multinodular goiter)
- Any complication of hyperthyroidism or underlying medical condition that would put the participant at undue risk. This includes arrhythmia or tachyarrhythmia related to GD, such as atrial fibrillation or atrial flutter not sufficiently controlled with medications
- Graves' orbitopathy/Thyroid Eye Disease (GO/TED) requiring systemic therapy (eg, corticosteroids), orbital injections, orbital surgery, or orbital radiation, or expected immediate surgical intervention and/or planned corrective surgery/irradiation or medical therapy during the study
Where in United States
Also in 2 other countries, 6 sites
- Albany Medical College Community EndocrinologyAlbany, United StatesContact: Robert BuschTaking people
- University of MichiganAnn Arbor, United StatesContact: Tae-Hwa ChunTaking people
- Asheville Clinical ResearchAsheville, United StatesContact: Lauren BernsteinTaking people
- Profound Research LLC at Tri-City Primary CareCarlsbad, United StatesContact: Jamil Alkhaddo, MDTaking people
- Research Institute Of DallasDallas, United StatesContact: Heidi Shea, MDTaking people
- Metro Detroit Endocrinology CenterDearborn, United StatesContact: Ayman Elkadry, MDTaking people
- Frontier Medical Center - Academy of Diabetes Thyroid and EndocrineEl Paso, United StatesContact: Sergio RovnerTaking people
- Profound ResearchFarmington Hills, United StatesContact: Gary Edelson, MDTaking people
- Northeast Florida Endocrine & Diabetes Associates (NEFEDA) - Orange Park LocationFleming Island, United StatesContact: Senan Sultan, MDTaking people
- The Center for Diabetes and Endocrine CareFort Lauderdale, United StatesContact: Sam Lerman, MDTaking people
- Clinic of EndocrinologyHouston, United StatesContact: Amir Hassan, MDTaking people
- Juno ResearchHouston, United StatesContact: Damaris Vega, MDTaking people
- Tekton Research IrvingIrving, United StatesContact: Pablo Mora, MDTaking people
- University of Florida Jacksonville College of MedicineJacksonville, United StatesContact: Christian KochTaking people
- Truman Medical CenterKansas City, United StatesContact: Rajib Bhattacharya, MDTaking people
- Ilumina Medical Research LLCKissimmee, United StatesContact: Max Sosa-Pagan, MDTaking people
- Johnson County Clin-Trials, Inc.Lenexa, United StatesContact: Thomas Kreamer, MDTaking people
- Biopharma Informatic, LLCMcAllen, United StatesContact: Gloria Ortiz, MDTaking people
- Tekton Research - McKinneyMcKinney, United StatesContact: Muhammad Siddiqui, MDTaking people
- Southern Endocrinology Associates PAMesquite, United StatesContact: Sumana Gangi, MDTaking people
- Oceane 7 Medical & Research Center, Inc.Miami, United StatesContact: Orlando FernandezTaking people
- Endocrine Associates of West Village PCNew York, United StatesContact: Anastasios Manessis, MDTaking people
- Diabetes Associates Medical GroupOrange, United StatesContact: Ivy-Joan Madu, MDTaking people
- Havana Research Institute LLCPasadena, United StatesContact: John De Beixedon, MDTaking people
- Pasadena Clinical TrialsPasadena, United StatesContact: Tzu-Jen TzaoTaking people
- Wake Internal Medicine ConsultantsRaleigh, United StatesContact: Juman Takeddin, MDTaking people
- San Jose Clinical TrialsSan Jose, United StatesContact: Richard CherlinTaking people
- Consano Clinical ResearchShavano Park, United StatesContact: Daniel Katselnik, MDTaking people
- Alliance for Multispecialty Research LLCWichita, United StatesContact: Terry KleinTaking people
About the trial
What the trial wants to find out
The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it.
Read full original descriptionShow less
The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment.
The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment.
More information can be found here: https://clinicaltrials.argenx.com/vitalithy
The 5 groups in the trial
- Part A - efgartigimod PH20 SC PFSTreatment being tested
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.
Treatment: Efgartigimod PH20 SC
- Part A - placebo PH20 SC PFSPlacebo, for comparison
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.
Treatment: Placebo PH20 SC
- Part B - efgartigimod PH20 SC PFSTreatment being tested
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.
Treatment: Efgartigimod PH20 SC
- Part B - placebo PH20 SC PFSTreatment being tested
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.
Treatment: Placebo PH20 SC
- Part C - efgartigimod PH20 SC PFSTreatment being tested
Participants will receive efgartigimod PH20 SC PFS in the part C open-label treatment period
Treatment: Efgartigimod PH20 SC
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs
- Plain-language title
- Efgartigimod injections for adults with Graves' disease not controlled by thyroid medicinesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 3 November 2026